Cagrilintide 5MG is a long-acting, lipidated analog of human amylin, engineered with structural modifications (including 14E/17R substitutions and a fatty-acid acyl chain) designed to resist amyloid aggregation and extend receptor residence time relative to native amylin or pramlintide Amylin, released with insulin from beta cells in the pancreas, induces its satiating effect via both the homoeostatic and hedonic regions of the brain, and cagrilintide's development addressed two main barriers: preventing amylin protein aggregation and extending the analog's half-life. This engineering profile has made cagrilintide a widely used tool compound in receptor-pharmacology and energy-homeostasis research.

​

Research Findings of Interest

Receptor engagement: Cryo-electron microscopy studies have characterized how cagrilintide engages AMY1, AMY2, AMY3, and calcitonin receptors in active, Gs-coupled conformations, with the peptide's lipid modification and an ionic lock creating interaction patterns that support extended stability in solution.  (Superpower)

Mechanism studies (rodent models): Research in mouse models has demonstrated that cagrilintide's body-weight effects depend on the presence of AMY1R and AMY3R receptors, an area where investigators note more work is needed at the receptor and genomic level to understand the mechanisms underlying amylin analog effects on energy metabolism.  (The Lancet)

​

Species-dependent effects: Studies note that while amylin analogs like cagrilintide mediate sustained weight loss in rats, they suppress feeding less robustly and only transiently in mice, an area of ongoing investigation into dorsal vagal complex neural circuitry.

​

Combination-mechanism research: Published pharmacology reviews describe cagrilintide's amylin-analog activity as mechanistically distinct from, but additive with, GLP-1 receptor agonist pathways in preclinical appetite-regulation models.